Dr Barber is a consultant physician and healthcare services professional with expertise spanning HIV and sexual/reproductive health (genitourinary medicine). He is a national and international leader in the HIV field who drives clinical improvements whilst always championing patient centred and holistic care, collaborative and shared decision making and instilling a culture of exceptional treatment.

He is clinical lead for a bespoke service focused on HIV, frailty and ageing. Dr Barber is accustomed to gathering, disseminating and leveraging data to streamline and deliver improvements across HIV and sexual and reproductive health. He was awarded his MD by the University of Cambridge in 2019 for research in HIV-related neurocognitive impairment.

Dr Barber is currently chair of the education and scientific subcommittee for the British HIV Association (BHIVA) as well as being associate editor for the journal Sexually Transmitted Infections and editor for HIV Research and Clinical Practice.



limited French

• Madge S, Barber TJ, Hunter A, et al. Descriptive account of 18 adults with known HIV infection hospitalised with SARS-CoV-2 infection. Sexually Transmitted Infections. Published Online First: 02 September 2020. doi: 10.1136/sextrans-2020-054660
• Cimen C, Emecen AN, Barber TJ. Attitude of infectious diseases physicians in Turkey about HIV pre-exposure prophylaxis: results of an online survey. International Journal of STD & AIDS 2020, Vol. 31(7) 665–670.
• Psomas CK, Waters L, Barber T et al. Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science. Journal of Virus Eradication, 04 Nov 2019, 5(4):245-252.
• Cox J, Gutner C, Kronfli N… Barber TJ et al. (2019) A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review. PLOS ONE 14(8): e0220060.
• Barber TJ. Bictegravir and dolutegravir: head-to-head at 96 weeks. Lancet HIV. May 05, 2019. DOI:
• Barber TJ, Borok T, Suchak T, et al. Having children outside a heterosexual relationship: options for persons living with HIV. Sex Transm Infect 2019;95: 99–101.
• Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B. CSF Inflammatory Markers and Neurocognitive Function after Addition of Maraviroc to Monotherapy darunavir/ritonavir in stable HIV patients: The CINAMMON Study. Journal of Neurovirology. Feb 2018 24(1): 98-105.
• Barber TJ, Saunders JM, Barnett N. Person-centred care and HIV: challenges and solutions. Sex Transm Infect 2018;94:582-584.
• Parry S, Zetler S, Kentridge A, Petrak J, Barber TJ. Simple screening for neurocognitive impairment in routine HIV outpatient care: is it deliverable? AIDS Care. Online: 14 Mar 2017.
• Barber TJ, Bansi L, Pozniak A, Asboe D, Nelson M, Moyle G, Davies N, Margetts A, Ratcliffe D, Catalan J, Boffito M, Gazzard B. Low levels of neurocognitive impairment detected in screening HIV-infected MSM: The MSM Neurocog Study. International Journal of STD and AIDS. Online first Published August 10, 2016.
• Barber TJ, Moyle G, Hill A, Jagjit Singh G, Scourfield A, Yapa HM, Waters L, Asboe D, Boffito M, Nelson M. A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors. HIV Clin Trials. 2016 May;17(3):123-30.

Dr Barber currently has research projects examining aspects of HIV and ageing, the interaction of HIV on SARS CoV-2 antibody positivity and a planned clinical trial looking at the action of doravirine in patients with known antiretroviral associated resistance mutations. His research background is in HIV vaccine studies, phase three antiretroviral trials and HIV related neurocognitive impairment.